Zelgen Biopharmaceuticals to Present Cancer Drugs at American Oncology Conference; Shares Up 4%

MT Newswires Live

2025/06/03

Suzhou Zelgen Biopharmaceuticals (SHA:688266) will present two cancer drugs at the 2025 American Society of Clinical Oncology Annual Meeting after showing positive results during their clinical trials, according to a Tuesday disclosure on the Shanghai bourse.

Alveltamig and Nilvanstomig, with the respective codes ZG006 and ZG005, are currently undergoing clinical trials. These drugs have shown safety, efficiency, and high tolerability in patients during the studies, the Chinese drugmaker company said.

The company's shares jumped 4% in recent trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540741251"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540741251\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540741251?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 13:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540741251","market":"us","top_or_hot":-1,"title":"Zelgen Biopharmaceuticals to Present Cancer Drugs at American Oncology Conference; Shares Up 4%","media":"MT Newswires Live","content":"<html><body><p> Suzhou Zelgen Biopharmaceuticals (SHA:688266) will present two cancer drugs at the 2025 American Society of Clinical Oncology Annual Meeting after showing positive results during their clinical trials, according to a Tuesday disclosure on the Shanghai bourse.</p><p>Alveltamig and Nilvanstomig, with the respective codes ZG006 and ZG005, are currently undergoing clinical trials. These drugs have shown safety, efficiency, and high tolerability in patients during the studies, the Chinese drugmaker company said.</p><p>The company's shares jumped 4% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zelgen Biopharmaceuticals to Present Cancer Drugs at American Oncology Conference; Shares Up 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZelgen Biopharmaceuticals to Present Cancer Drugs at American Oncology Conference; Shares Up 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-03 13:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Suzhou Zelgen Biopharmaceuticals (SHA:688266) will present two cancer drugs at the 2025 American Society of Clinical Oncology Annual Meeting after showing positive results during their clinical trials, according to a Tuesday disclosure on the Shanghai bourse.</p><p>Alveltamig and Nilvanstomig, with the respective codes ZG006 and ZG005, are currently undergoing clinical trials. These drugs have shown safety, efficiency, and high tolerability in patients during the studies, the Chinese drugmaker company said.</p><p>The company's shares jumped 4% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4107","symbol_name":"财产与意外伤害保险","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2540741251","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540741251","pubTimestamp":1748928644,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Suzhou Zelgen Biopharmaceuticals  will present two cancer drugs at the 2025 American Society of Clinical Oncology Annual Meeting after showing positive results during their clinical trials, according to a Tuesday disclosure on the Shanghai bourse.Alveltamig and Nilvanstomig, with the respective codes ZG006 and ZG005, are currently undergoing clinical trials. These drugs have shown safety, efficiency, and high tolerability in patients during the studies, the Chinese drugmaker company said.The company's shares jumped 4% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688266":"泽璟制药","BK4107":"财产与意外伤害保险","BK4117":"多元化保险","AFG":"美国金融集团有限公司","BK0239":"医药制造"},"translate_title":"Zelgen Biopharmaceuticals将在美国肿瘤学会议上展示癌症药物；股价上涨4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688266":0.9,"AFG":1},"content_text":"Suzhou Zelgen Biopharmaceuticals (SHA:688266) will present two cancer drugs at the 2025 American Society of Clinical Oncology Annual Meeting after showing positive results during their clinical trials, according to a Tuesday disclosure on the Shanghai bourse.Alveltamig and Nilvanstomig, with the respective codes ZG006 and ZG005, are currently undergoing clinical trials. These drugs have shown safety, efficiency, and high tolerability in patients during the studies, the Chinese drugmaker company said.The company's shares jumped 4% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}